PMV Pharmaceuticals, Inc.
$1.16
-0.43%PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.8).
Valuation inputs: P/E -0.8, earnings yield N/A, momentum -0.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -74.2%, ROIC -79.5%).
Profitability stack: net margin 0.0%, ROE -74.2%, ROIC -79.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +10.2%, momentum -0.4%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
PMV Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
PMV Pharmaceuticals, Inc. Fair Value Envelope
No Revenue Data
PMVP has not reported any revenue values in the available annual periods.
PMV Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
PMVP has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
PMVP has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
PMVP has not reported any net profit margin values in the available annual periods.
PMV Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
PMV Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
PMV Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that PMVP stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 5.00, with estimates ranging from a low of 5.00 to a high of 5.00.
The consensus 1-year price target stands at 5.00, with estimates ranging from a low of 5.00 to a high of 5.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
PMV Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $159K and sold $2.91M worth of PMVP shares, resulting in $2.75M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
1.7M
2.72M
-2.7M
-$2.72M
9-12 Months
167.5K
159.12K
176.4K
183.93K
-25K
-$25K
Top Buyers
Baum Charles M
Director
$32K
Stelzer Laurie
Director
$32K
Levine Arnold J
Director
$32K
Heyman Richard A.
Director
$32K
Flowers Kirsten
Director
$32K
Top Sellers
Orbimed Advisors Llc
10 Percent Owner
$2.42M
Mack David Henry
Director, Officer: President And Ceo
$364K
Jalota Deepika
Officer: Chief Development Officer
$35K
Gallagher Carol Giltner
Director
$32K
Carulli Michael
Officer: Chief Financial Officer
$30K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $2.75M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
No Dividend Yield Data
PMVP has not reported any dividend yield values in the available annual periods.
pmvp Dividend History
Learning Layer
Related Guides
Build conviction on PMVP by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.